## Abstract ## BACKGROUND. Telangiectatic osteosarcoma (TOS) is a rare subtype of osteosarcoma (OS). The authors reviewed their experience with TOS to characterize its histologic, radiologic, and clinical features. ## METHODS. The authors reviewed records, pathology material, and imaging studies
Osteosarcoma of the pelvis in children and young adults: The St. Jude Children's Research Hospital experience
โ Scribed by Raya Saab; Bhaskar N. Rao; Carlos Rodriguez-Galindo; Catherine A. Billups; Tamra N. Fortenberry; Najat C. Daw
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 94 KB
- Volume
- 103
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract ## BACKGROUND Despite improvements in therapy for osteosarcoma, approximately 4โ10% of patients experience a local recurrence and have a poor prognosis. ## METHODS The authors analyzed prognostic factors for survival in 26 patients with a local recurrence of osteosarcoma who were tre
## BACKGROUND. Bone sarcomas of the head and neck are difficult to resect. The authors reviewed their institutional experience with these tumors to characterize patients' clinical findings and to assess the impact of surgical resection on outcome. ## METHODS. The records of the 28 patients with b
## Background. Because the natural history of pediatric patients with metastatic nonrhabdomyosarcomatous soft-tissue sarcomas (NRSTS) had not been well described, we retrospectively reviewed our single-institution experience with these tumors. Procedure. We identified 26 patients with metastatic N
Background. Brain metastasis has been considered a rare event in osteosarcoma, although with prolonged survival an increasing incidence has been suggested. There have been no prior reports of long-term survivors among patients with this complication. Methods. The authors describe a child treated fo
## role of irradiation in those patients with IRS Group IV disease is at present confined to palliative roles until the time when more effective chemotherapy will mandate the decision to treat primary disease for curative measures.